OS Advantage of Gotistobart Over Docetaxel in Patients with anti-PD‑(L)1- and Chemotherapy-Resistant Metastatic Squamous NSCLC By Ogkologos - April 14, 2026 81 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the stage 1 of the phase III PRESERVE-003 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Adopts a Positive Opinion for a New Route of Administration Together with a New Pharmaceutical Form and a New Strength for Isatuximab National Study Examines Genetic Testing to Inform Follow-up Care for Cancer Survivors Taletrectinib Demonstrates Durable Long-Term Efficacy in Both TKI-naïve and Crizotinib-pretreated Patients with Advanced ROS1-positive NSCLC MOST POPULAR Durvalumab Extends Lives of People with Early-Stage Small Cell Lung Cancer June 25, 2024 ctDNA-Guided Therapy with Pertuzumab plus Trastuzumab for HER2-Amplified mCRC November 23, 2021 Addition of an EGFR Antibody to Fluorouracil/Folinic Acid Maintenance Therapy in... September 22, 2021 More Evidence that One HPV Vaccine Dose Protects against Cancer-Causing Infections June 3, 2022 Load more HOT NEWS Improved Survival Benefit with Encorafenib plus Cetuximab plus mFOLFOX6 in First-Line... FDA Grants Accelerated Approval to Asciminib for Newly Diagnosed Chronic Myeloid... Cholesterol Drug May Help Protect the Heart during Chemotherapy for Lymphoma What to Know About Treatment Options Before and After Surgery for...
